Q2 Earnings Forecast for TWST Issued By William Blair

Twist Bioscience Co. (NASDAQ:TWST) – Stock analysts at William Blair issued their Q2 2026 earnings estimates for Twist Bioscience in a research report issued to clients and investors on Tuesday, February 4th. William Blair analyst M. Larew forecasts that the company will post earnings of ($0.41) per share for the quarter. The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.75) earnings per share.

Several other research firms also recently commented on TWST. Scotiabank raised their price objective on Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday. Barclays dropped their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Stock Down 1.4 %

Shares of Twist Bioscience stock opened at $52.02 on Wednesday. The stock’s fifty day moving average is $48.63 and its 200 day moving average is $46.21. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience in the third quarter worth about $34,000. Van ECK Associates Corp raised its position in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares in the last quarter. Signaturefd LLC raised its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience during the third quarter valued at approximately $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Patrick John Finn sold 10,340 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $496,320.00. Following the transaction, the chief operating officer now owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. The trade was a 4.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,707 shares of company stock valued at $2,343,623 in the last quarter. 3.01% of the stock is currently owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.